AU2017903033A0 - Bdm-i therapy - Google Patents
Bdm-i therapyInfo
- Publication number
- AU2017903033A0 AU2017903033A0 AU2017903033A AU2017903033A AU2017903033A0 AU 2017903033 A0 AU2017903033 A0 AU 2017903033A0 AU 2017903033 A AU2017903033 A AU 2017903033A AU 2017903033 A AU2017903033 A AU 2017903033A AU 2017903033 A0 AU2017903033 A0 AU 2017903033A0
- Authority
- AU
- Australia
- Prior art keywords
- bdm
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000002560 therapeutic procedure Methods 0.000 title 1
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/635,600 US20200237717A1 (en) | 2017-08-01 | 2018-07-30 | Treatment of Staphylococcal and Enterococcal Infections Using Substituted Nitrostyrene Compounds |
CN201880061684.2A CN111194213A (en) | 2017-08-01 | 2018-07-30 | Treatment of staphylococcal and enterococcal infections using substituted nitrostyrene compounds |
PCT/AU2018/050788 WO2019023741A1 (en) | 2017-08-01 | 2018-07-30 | Treatment of staphylococcal and enterococcal infections using substituted nitrostyrene compounds |
AU2018310749A AU2018310749A1 (en) | 2017-08-01 | 2018-07-30 | Treatment of Staphylococcal and Enterococcal infections using substituted nitrostyrene compounds |
CA3071577A CA3071577A1 (en) | 2017-08-01 | 2018-07-30 | Treatment of staphylococcal and enterococcal infections using substituted nitrostyrene compounds |
EP18841431.2A EP3661496A4 (en) | 2017-08-01 | 2018-07-30 | Treatment of staphylococcal and enterococcal infections using substituted nitrostyrene compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2017903033A0 true AU2017903033A0 (en) | 2017-08-10 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3463464A4 (en) | Combination therapy | |
EP3551285A4 (en) | Defibrillator | |
EP3732195A4 (en) | Cytotoxicity-inducing therapeutic agent | |
EP3291824A4 (en) | Antimicrobial therapy | |
EP3651772A4 (en) | Combination cancer therapy | |
EP3601536A4 (en) | Treatment methods | |
EP3768258A4 (en) | Combination therapy | |
EP3619238A4 (en) | Cytotoxicity-inducing therapeutic agent | |
EP3515414A4 (en) | Combination therapy | |
EP3413927A4 (en) | Cancer therapy | |
EP3668507A4 (en) | Combination therapy | |
EP3630118A4 (en) | Combination therapy | |
EP3733175A4 (en) | Cancer therapeutic | |
EP3609520A4 (en) | Targeted combination therapy | |
EP3419959A4 (en) | Combination therapy | |
EP3606544A4 (en) | Minigene therapy | |
EP3893874A4 (en) | Crenolanib combination therapy | |
EP3612522A4 (en) | Therapeutic compounds | |
EP3576746A4 (en) | Cancer therapeutic | |
EP3717003A4 (en) | Gp96-based cancer therapy | |
EP3675891A4 (en) | Combination cancer therapy | |
EP3721886A4 (en) | Therapeutic method | |
EP3624849A4 (en) | Combination therapy using ascochlorin derivative | |
EP3655106A4 (en) | Combination drug therapy | |
EP3639835A4 (en) | Use ofcimicifugae foetidae |